Combination therapy for chronic hepatitis C: Interferon and ribavirin

Hospital Medicine

Volumn 60, Issue 5, 1999, Pages 357-361

  Christie, John M L ^a   Chapman, Roger W G ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

DRUG COMBINATION; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; RECURRENT DISEASE; REVIEW; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; LIVER NEOPLASMS; RECURRENCE; RIBAVIRIN;

EID: 0033128759     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.1999.60.5.1116     Document Type: Article

References (24)

1. Alter MJ (1997) Epidemiology of hepatitis C. Hepatology 26(suppl l):62-5
2. Alter MJ, Margolis HS, Krawczynski K et al (1992) The natural history of community-acquired hepatitis C in the United States. NEnglJMed327: 273-8
3. Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24: 289-93
4. Bodenheimer HC, Lindsay KL, Davis GL et al (1997) Tolerance and efficacy of oral ribavirin treatment of hepatitis C: a multicentre trial. Hepatology 26: 473-7
5. Brillanti S, Garson J, Foli M et al (1994) A pilot study of combination therapy with ribavirin plus interferon alfa for alfa-interferon resistant chronic hepatitis C. Gastroenterology 107: 812-7
6. Chemello L, Cavaletto L, Bernardinello E, Guido M, Pontisso P, Albert! A (1995) The effect of Interferon alfa and ribavirin combination therapy in naïve patients with chronic hepatitis C. J Hepatol 23: 8-12
7. Davis GL, Lau JYN ( 1997) Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 26(S): 122-7
8. Davis GL, Estaban-Mur R, Rutstgi V et al (1998) Recombinant interferon alfa-2b alone or in combination with ribavirin for retreatment of interferon relapse in chronic hepatitis C. N EnglJ Med 339: 1493-9
9. DiBisceglie AM, Shindo M, Fong T-L et al (1992) Pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16:649-54
10. Dusheiko G, Main J, Thomas H et al (1996) Ribavirin treatment for chronic hepatitis C: results of a placebo controlled study. J Hepatol 25: 591-8
11. Knodell RG, Ishak KG, Black WC et al (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1: 431-5
12. Lindsay KL (1997) Therapy of hepatitis C: overview. Hepatology 26(S1): 71-7
13. Marcellin P, Boyer N, Degott C et al (1994) Long-term histologie and viral changes in patients with chronic hepatitis C who responded to alpha interferon. Liver 14: 302-7
14. Marcellin P, Boyer N, Gervais A et al (1997) Long term histologie improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-a therapy. Ann Intern Med 127:875-81
15. McHutchinson J, Gordon S, Schiff E et al (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N EnglJ Med 339: 1485-92
16. Mutimer D, Harrison R, O'Donnell K et al (1995) Hepatitis C virus infection in the British asymptomatic blood donor. J Viral Hepatitis 2: 47-53
17. National Institutes of Health Consensus Development Conference Panel Statement (1997) Management of hepatitis C. Hepatology 26: 2S-10S
18. Patterson JL, Fernandez-Larson R (1990) Molecular action of ribavirin. Rev Infect Dis 12: 1132-46
19. Poynard T, Leroy V, Cohard M et al ( 1996) Meta-analysis of interferon randomised trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 24: 778-89
20. Poynard T, Marcellin P, Lee S et al (1998) Randomised trial of interferon alfa-2b plus ribavirin 48 weeks or 24 weeks vs interferon alfa-2b plus placebo 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352: 1426-32
21. Reichard O, Andersson J, Schvarcz R (1991) Ribavirin treatment for chronic hepatitis C. Lancet 337: 1058-61
22. Reichard O, Glaumann H, Fryden A et al (1995) Two-year biochemical, virological, and histological follow up in patients with chronic hepatitis C responding in a sustained fashion to alfa-2b treatment. Hepatology 21: 918-22
23. Reichard O, Norkans G, Fryden A et al ( 1998) A randomised, double blind, placebo-controlled trial of interferon-a-2b with and without ribavirin for chronic hepatitis C. Lancet 351: 83-7
24. Schalm SW, Brouwer JT, Chemello L et al (1996) Interferon ribavirin combination therapy for chronic HCV Dig Dis Sd4: 131s-134s